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584Objectives:Average 2-year survival after cardiac transplantation is approximately 80%. The evolution and sub-
sequent approval of larger pulsatile and, more recently, continuous flow mechanical circulatory support (MCS)
technology for destination therapy (DT) offers the potential for triage of some patients awaiting cardiac trans-
plantation to DT.
Methods: The National Heart, Lung, and Blood Institute Interagency Registry for Mechanically Assisted Cir-
culatory Support (INTERMACS) is a national multi-institutional study of long-term MCS. Between June 2006
and December 2011, 127 pulsatile and 1160 continuous flow pumps (24% of total primary left ventricular assist
devices [LVADs]) carried an initial strategy of DT therapy.
Results: By multivariable analysis, risk factors (P<.05) for mortality after DT included older age, larger body
mass index, history of cancer, history of cardiac surgery, INTERMACS level I (cardiogenic shock), dialysis, in-
creased blood urea nitrogen, use of a pulsatile flow device, and use of a right ventricular assist device (RVAD).
Among patients with a continuous flow LVAD who were not in cardiogenic shock, a particularly favorable sur-
vival was associated with no cancer, patients not in cardiogenic shock, and blood urea nitrogen less than 50
mg/dL, resulting in 1- and 2-year survivals of 88% and 80%.
Conclusions: (1) Evolution from pulsatile to continuous flow technology has dramatically improved 1- and
2-year survivals; (2) DT is not appropriate for patients with rapid hemodynamic deterioration or severe right
ventricular failure; (3) important subsets of patients with continuous flow DT now enjoy survival that is
competitive with heart transplantation out to about 2 years. (J Thorac Cardiovasc Surg 2012;144:584-603)Durable mechanical circulatory support (MCS) systems
have evolved into therapies suitable for multiyear support.
In the United States, the historical development of such sup-
port devices was linked to cardiac transplantation, address-
ing the universal shortage of suitable donors for cardiac
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The Journal of Thoracic and Cardiovascular Surgbeen implanted as bridge-to-transplant therapy, with a small
subset implanted as a bridge-to-ventricular recovery. When
MCS therapy in the United States was expanded to include
the intent of long-term ‘‘destination’’ therapy (DT) in
2003,1 Medicare and most other providers considered DT
appropriate only for patients not considered eligible for car-
diac transplantation, based on inferior demonstrated sur-
vival with MCS compared with transplantation.
However, the landscape of devices, their expected dura-
bility, and patient outcomes have rapidly evolved over the
past 4 years. This study was undertaken to examine, through
a national MCS database, the hypothesis that ‘‘mechanical
circulatory support as DT has evolved to a level that justifies
consideration of selected patients for DTwho are transplant
eligible.’’MATERIALS AND METHODS
Interagency Registry for Mechanically Assisted
Circulatory Support Database
Interagency Registry for Mechanically Assisted Circulatory Support
(INTERMACS) is a registry for durable (suitable for patient discharge)
MCS devices approved by the US Food and Drug Administration (FDA)
and implanted in the United States. The registry is sponsored by the Na-
tional Heart, Lung, and Blood Institute (NHLBI). The term ‘‘interagency’’
emphasizes the unique collaboration between the NHLBI as the funding
and scientific support agency, the FDA as the regulatory agency, and the
Center for Medicaid and Medicare Services (CMS) as the federal reim-
bursement agency.2 Information collected in the INTERMACS databaseery c September 2012
Abbreviationsand Acronyms
CMS ¼ Center for Medicaid and
Medicare Services
DT ¼ destination therapy
EQ ¼ EuroQol
FDA ¼ Food and Drug Administration
INTERMACS ¼ Interagency Registry for
Mechanically Assisted
Circulatory Support
LVAD ¼ left ventricular assist device
MCS ¼ mechanical circulatory support
NHLBI ¼ National Heart, Lung, and Blood
Institute
NYHA ¼ New York Heart Association
RVAD ¼ right ventricular assist device
VAD ¼ ventricular assist device
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Dincludes patient profile data, implant and device data, scheduled follow-up
information, and event-driven data. The occurrence of infection, device
failure, neurologic events, and death trigger the acquisition of additional
relevant data elements. Participation in INTERMACS is a requirement
for hospitals to be reimbursed by CMS for the implantation ofMCS devices
intended for permanent or ‘‘destination’’ therapy (DT). Patient enrollment
in INTERMACS was commenced on June 23, 2006. Between June 23,
2006, and December 31, 2011, a total of 5614 patients who received a du-
rable ventricular assist device (VAD) or total artificial heart were entered
into the INTERMACS database.
Study Group
Of these 5614 registry patients, 1287 patients received a VAD as DT
(Figure 1). These 1287 patients are the subject of this analysis. The study
inclusion criteria are listed in Table 1. At the time of implant, 1256 patients
received a left VAD (LVAD) only, and 31 received biventricular support. In
the overall experience, 127 DT implants were pulsatile devices and 1160
were continuous flow pumps (see again Figure 1).All Primary imp
left ventricular
n= 5407
All Patients, n
Previous durable VAD at 
entry into registry
N=196
BiVAD
N=31
Pulsatile Flow
N=7
Continuous 
N=24
Destination T
Patients, n=
FIGURE 1. Categorization of all 5614 patients entered into INTERMACS betw
(n ¼ 1287) constitutes the study group. INTERMACS, Interagency Registry for M
RVAD, right ventricular assist device; LVAD, left ventricular assist device; BiV
The Journal of Thoracic and CaMissing DT Patients From INTERMACS
Patients receiving MCS implants in the United States who are entered
into INTERMACS must fulfill 2 criteria: (1) the device implanted must
be FDA approved and (2) the patient must provide informed consent for en-
try of his or her data into INTERMACS. For FDA-approved devices,
INTERMACS receives data on device implant and survival/mortality at
48 hours for all patients, even if consent is not obtained. Further follow-
up is available only if patient consent is obtained. INTERMACS audits
and screening logs indicate that 9.6% of patients suitable for INTERMACS
were not entered with full data collection owing to failure to obtain in-
formed consent. INTERMACS receives no information for patients who re-
ceive an investigational device as part of a clinical trial.
Follow-up
All patients are followed up as part of the requirements of INTERMACS
until 1 of 3 end points is reached: death, transplant, or device explant for
recovery. Data collection at routine follow-up intervals (see Appendix
Table 1) occurs for a variety of routine clinical variables in addition to
data forms that are ‘‘triggered’’ by specific adverse events. Among the
1287 DT patients, follow-up was available in greater than 99% at the
follow-up date of December 31, 2011.
Adverse Event Definitions
Standardized definitions for adverse events were established during the
initial phase of INTERMACS, developed with the participation and agree-
ment of experts in the field, FDA, and industry. The adverse event defini-
tions are included in Appendix Table 2.
INTERMACS Profiles
The INTERMACS profiles represent a reclassification of New York
Heart Association (NYHA) class IV heart failure.3 The profiles are listed
in Appendix Table 3.
Statistical Methods
Standard Kaplan-Meier actuarial methods as well as parametric depic-
tions were used to examine survival and freedom from other specific
events. Standardmethodswere used to examinewhether differences among
variables were likely due to chance. Competing outcomes depictions used
standard methodology as described by McGiffin and colleagues.4 Risklants for 
 support
LVAD
N=1256
= 5614
RVAD alone (no 
previous VAD)
N=11
Flow Continuous Flow
N=1136
Pulsatile  Flow
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herapy 
1287
een June 23, 2006, and December 31, 2011. The group Destination Therapy
echanically Assisted Circulatory Support; VAD, ventricular assist device;
AD, biventricular assist device.
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TABLE 1. INTERMACS June 2006–December 2011: Destination
therapy
Inclusion/exclusion criteria
Primary LVAD or BIVAD implant
Adults (aged 19 y at implant)
Patients consented to participate in INTERMACS
Device strategy at time of implant: destination therapy
Patient received an FDA-approved device
Implant dates: June 23, 2006–December 31, 2011
Study group description
Institutions contributing data: 104
Patients: 1287
Total deaths with a device in place: 314
Total heart transplants: 52
Total device removal due to recovery: 3
Total device exchanges: 52
Total transfers*: 11
Follow-up: through December 31, 2011
LVAD, Left ventricular assist device; BIVAD, biventricular assist device; INTER-
MACS, Interagency Registry for Mechanically Assisted Circulatory Support; FDA,
United States Food and Drug Administration. *Eleven patients had their care trans-
ferred to a non-INTERMACS center and were censored at the time of care transfer.
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Dfactors for mortality were examined via multivariable analysis in the hazard
function domain. The variables entered into the multivariable model are
listed in Appendix Table 4. The risk factor equations are listed in
Appendix Table 5.
Transplant Survival
Expected survival after cardiac transplantation was drawn from the reg-
istry of the International Society for Heart and Lung Transplantation.5
Quality of Life Studies
All institutions were encouraged to apply quality of life instruments to
patients receiving MCS, beginning before implantation and repeated at
specified intervals thereafter. The selected quality of life instruments in-
cluded the EuroQol (EQ)-5D and the EQ visual analog scale score. The
EQ-5D is a standardized instrument designed as a measure of health out-
come and applicable to a wide range of health conditions and treatments.
This test is primarily designed for self-completion by the respondents, ex-
amining the dimensions of mobility, self-care, usual activities, pain/dis-
comfort, and anxiety/depression. The EQ visual analog scale instrument
includes a standard vertical 20-cm visual analog scale (similar toTABLE 2. Primary device strategy by year of implant: June 2006–Decem
Implant
Device strategy
2006
No. (%)
2007
No. (%)
20
No.
Bridge to recovery 4 (3.9) 14 (4.0) 15 (
Bridge to transplant* 45 (43.7) 148 (42.6) 367 (
Bridge-to-transplant candidacy 36 (35.0) 132 (38.0) 302 (
Destination therapyy 16 (15.6) 47 (13.5) 47 (
Rescue therapy 2 (1.9) 6 (1.7) 12 (
Other 0 (0.00) 0 (0.00) 0 (
Total 103 347 7
*Patient currently listed for transplant. yPatient definitely not eligible for transplant. zOne
study group.
586 The Journal of Thoracic and Cardiovascular Surga thermometer) for recording an individual’s self-rating regarding his or
her personal general health–related quality of life state.RESULTS
Evolution of DT
During the early phase of INTERMACS, continuous
flow technology was not yet FDA approved for adult pa-
tients. During the era in which essentially only pulsatile
pumps were entered into INTERMACS (June 2006–De-
cember 2007), only 13% of pumps were implanted with
a strategy of DT. With the approval of the HeartMate II
continuous flow device (Thoratec Corporation, Pleasanton,
Calif) for DT in January 2010, the number and proportion
of pumps implanted as DT progressively increased (Table
2). During the year 2011, 96% of primary device implants
(for any strategy) were continuous flow pumps (Figure 2).
DT accounted for 38% of implants during 2011, and all DT
patients received continuous flow devices (Figure 3).Reasons for Transplant Ineligibility
A variety of contraindications to transplants were cited,
some of which were absolute while others were potentially
reversible during VAD support (Table 3). The most fre-
quently cited contraindication was advanced age (38% of
patients), followed by renal dysfunction (20%), high body
mass index (14%), and pulmonary hypertension (12%).
Approximately 35% were considered potentially modifi-
able, indicating the possibility of later suitability for
transplantation.Outcome of Patients With Initial DT Strategy
As noted in the previous section, many of the contraindi-
cations to transplantation at the time of device implant were
considered potentially reversible. As their clinical situation
evolved over time, some patients were reconsidered for car-
diac transplantation, or, potentially, for device explant.
These events are tracked by the competing outcomes depic-
tions in Figure 4 for pulsatile devices and Figure 5 for con-
tinuous flow devices. In the current era of continuous flowber 2011
year
08
(%)
2009
No. (%)
2010
No. (%)
2011
No. (%) Total
2.0) 12 (1.2) 12 (0.8) 15 (0.9) 72
49.4) 491 (49.4) 463 (28.9) 370 (22.8) 1884
40.6) 433 (43.6) 598 (37.4) 600 (37.0) 2101
6.3) 47 (4.7) 511 (31.9) 620 (38.3) 1288z
1.6) 5 (0.5) 8 (0.5) 5 (0.3) 38
0.00) 5 (0.5) 9 (0.6) 10 (0.6) 24
43 993 16014 1620 5407
patient, aged 18 years, was considered a pediatric patient and was not included in the
ery c September 2012
Pulsatile Flow Intracorporeal LVAD Pump (+/- RVAD)
Continuous Flow Intracorporeal LVAD Pump (+/- RVAD)
I
m
p
l
a
n
t
s
 p
e
r
 
y
e
a
r
Cont Intra Pump           1                      1 464 843  1526                1548
Puls Intra TAH 2                    22                  22        24                  27                    15
Puls Intra Pump          82 263                183                    55 12                     2
Puls Para Pump 18 61                  74 71         36                    55
Pulsatile Flow Paracorporeal LVAD Pump (+/- RVAD)
Primary Implant Enrollment:  n=5407
Pulsatile Flow Intracorporeal TAH
FIGURE 2. Primary device implant by year, stratified by device type, for the entire INTERMACS experience. INTERMACS, Interagency Registry for Me-
chanically Assisted Circulatory Support; LVAD, left ventricular assist device; RVAD, right ventricular assist device; TAH, total artificial heart; Cont, con-
tinuous flow; Intra, intracorporeal; Puls, pulsatile; Para, paracorporeal.
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DDT devices, less than 5% of patients undergo transplanta-
tion or explant within 2 years.
Adverse Events
Infection and bleeding were the most common adverse
events, followed by respiratory failure, neurologic events,
and renal dysfunction (Table 4). Of note, the adverse event
profile differed between pulsatile and continuous flow
pumps (Table 4). Device malfunction, bleeding, infection,0
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FIGURE 3. Destination therapy device implants by year, stratified by dev
The Journal of Thoracic and Castroke, renal dysfunction, and respiratory failure all oc-
curred with a significantly higher event rate with pulsatile
pumps.
Device malfunction severe enough to require pump ex-
change or cause death was strikingly different between
pump types (Figure 6). The hazard function (instanta-
neous risk) for device failure progressively increased
over the 2 years of follow-up for pulsatile pumps,
whereas the hazard function for continuous flow devices2009 2010 2011
 Pump
al Pump
26 508              620
20 3                  0
estination Therapy:  n=1287
ice type. Cont, Continuous flow; Intra, intracorporeal; Puls, pulsatile.
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TABLE 3. Transplant contraindications—Adult primary implants:
INTERMACS June 2006–December 2011
Contraindications
No. (%)
(N ¼ 1287)
Modifiable
Renal dysfunction 256 (20)
High body mass index 182 (14)
Pulmonary hypertension 157 (12)
Still smoking 90 (7)
Severe diabetes 87 (7)
Alcohol abuse 41 (3)
Illicit drug use 40 (3)
Repeated noncompliance 40 (3)
Limited social support 38 (3)
Limited cognition/understanding 21 (1.6)
Malnutrition/cachexia 20 (1.6)
Severe depression 10 (0.8)
Musculoskeletal limitation 10 (0.8)
Risk of recurrent infection 9 (0.7)
Current infection 9 (0.7)
Heparin-induced thrombocytopenia 9 (0.7)
Recent pulmonary embolus 3 (0.2)
Nonmodifiable
Advanced age 487 (38)
Peripheral vascular disease 89 (7)
Pulmonary disease 80 (6)
History of solid-organ cancer 64 (5)
Patient refuses transplant 54 (4)
Frailty 48 (4)
Fixed pulmonary hypertension 41 (3)
Multiple sternotomies 32 (2)
History of lymphoma leukemia 29 (2)
Major stroke 18 (1.4)
Contraindication to immunotherapy 15 (1.2)
Other major psychiatric diagnosis 8 (0.6)
Allosensitization 6 (0.5)
Mediastinal radiation 4 (0.3)
Thoracic aortic disease 4 (0.3)
Other comorbidity 118 (9)
INTERMACS, Interagency Registry for Mechanical Circulatory Support.
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Dremained low and essentially constant. For pulsatile
pumps, the freedom from device exchange was only
51% at 24 months, compared with 94% for continuous
flow pumps.0.1
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3 %
24 %
0.3%Survival
The overall actuarial survival among all DT patients was
75% at 1 year and 62% at 2 years (Figure 7). The hazard
function shows a rapidly falling early phase that merges
with a constant phase at about 3 months.0.0
0 3 6 9 12 15 18 21 24
Months after Device Implant
Recovery
FIGURE 5. Competing outcomes depiction for continuous flow left ven-
tricular assist devices (LVAD) implanted with a strategy of destination ther-
apy. *The depiction is as in Figure 4.Cause of Death
The primary causes of death differed according to time
interval after implant as well as device type (Tables 5 and
6). Cardiac failure was the major cause of early mortality,588 The Journal of Thoracic and Cardiovascular Surgand 32% of those patients received their device while in
cardiogenic shock. No other specific cause of death was pre-
dominantly related to either device type or interval from im-
plant to death.Risk Factors for Mortality
Risk factors for mortality in the early and constant phases
identified by multivariable analysis are listed in Table 7.
Older age. The hazard ratio of 1.24 reflects the increase in
risk from age 60 to 70 years. Perhaps not surprising is the
finding that elderly patients receiving DT had a lower gen-
eral risk profile than did younger patients. Without risk ad-
justment, the actuarial survival for older and younger
patients was similar (Figure 8).
INTERMACS level 1. INTERMACS level 1 identifies
those patients in cardiogenic shock at the time of VAD im-
plant (see Appendix Table 3). The progressive decrease inery c September 2012
TABLE 4. Adverse event rates (events/100 patient-months) in the first 12 months for destination therapy patients
Adverse event
Pulsatile (n ¼ 127) Continuous (n ¼ 1160) Hazard
P valueEvents Rate Events Rate Ratio
Device malfunction 38 3.69 100 1.15 3.21 <.0001
Bleeding 150 14.56 1040 11.94 1.22 .008
Cardiac/vascular
Right heart failure 14 1.36 151 1.73 0.78 .75
Myocardial infarction 0 0.00 3 0.03 — —
Cardiac arrhythmia 55 5.34 339 3.89 1.37 .009
Pericardial drainage 10 0.97 54 0.62 1.57 .06
Hypertension* 27 2.62 73 0.84 3.13 <.0001
Arterial non-CNS thrombosis 5 0.49 17 0.20 2.49 .01
Venous thrombotic event 11 1.07 56 0.64 1.66 .03
Hemolysis 0 0.00 55 0.63 — —
Infection 236 22.91 705 8.09 2.83 <.0001
Neurologic dysfunction 30 2.91 162 1.86 1.57 .006
Renal dysfunction 30 2.91 141 1.62 1.80 <.0001
Hepatic dysfunction 7 0.68 50 0.57 1.18 .24
Respiratory failure 41 3.98 230 2.64 1.51 .004
Wound dehiscence 10 0.97 19 0.22 4.45 <.0001
Psychiatric episode 21 2.04 78 0.90 2.28 <.0001
Total burden 685 66.50 3273 37.56 1.77 <.0001
Hazard ratio, The rate for pulsatile pump divided by the rate for continuous flow pump. CNS, Central nervous system. *With current reporting, identification of hypertension with
continuous flow pumps is unreliable.
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Dthe proportion of patients in level 1 at implant over the
course of the study is documented in Table 8. The inferior
survival when DTwas undertaken in the face of cardiogenic
shock is apparent in Figure 9.
Severe right ventricular failure. Right ventricular failure
sufficient to require support with a biventricular assist de-
vice at the time of implant was the strongest predictor of
mortality in the constant phase (see again Table 7). The
need for biventricular support resulted in a marked* Includes RVADs implanted at time of LVAD 
and subsequent RVAD implantations
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ous flow pump; PFP, pulsatile flow pump; LVAD, left ventricular assist de-
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The Journal of Thoracic and Careduction in survival for both pulsatile and continuous
flow LVADs (Figure 10). The likelihood of right VAD
(RVAD) implant at the time of DT was 5.5% for pulsatile
LVADS but fell to 2.1% with continuous flow technology.
Among the 48 RVAD implants, 31 (65%) occurred at the
time of LVAD implant, 2 (4%) later the same day, 9
(19%) between 0 and 7 days, and 6 (12%) more than 7
days after LVAD (Figure 11). RVAD explant occurred in
9 (19%) of 48 patients receiving an RVAD. The duration
of RVAD support ranged from 2 to 37 days (mean, 18).
The likelihood of needing biventricular support was0
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FIGURE 7. Actuarial survival among 1287 patients receiving destination
therapy left ventricular assist device (LVAD) support. Patients are censored
at the time of transplant or explant due to recovery. The lower curve repre-
sents the hazard function. The dashed lines enclose the 70% confidence
limits. *See notation in Figure 4.
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TABLE 5. Causes of death in 1287 LVAD* destination therapy
patients: INTERMACS June 2006–December 2011
Primary cause
of death
Pulsatile flow pumps
Early (1 mo)
(n ¼ 13)
Later (>1 mo)
(n ¼ 53)
Total
(n ¼ 66)
No. % No. % No. %
Cardiac failure
RV failure 2 15 4 8 6 9
Arrhythmia/other 1 8 6 11 7 11
Infection 1 8 8 15 9 14
CNS event 5 38 7 13 12 18
Multiorgan failure 0 0 3 6 3 5
Respiratory failure 2 15 1 2 3 5
Bleeding
Gastrointestinal 0 0 0 0 0 0
Surgical 1 8 0 0 1 1
Other bleeding 1 8 2 4 3 5
Device failure 0 0 3 6 3 5
Renal failure 0 0 1 2 1 1
Hepatic failure 0 0 1 2 1 1
Malignancy 0 0 1 2 1 1
Arterial embolism 0 0 0 0 0 0
Cardiac tamponade 0 0 0 0 0 0
Withdrawal of support 0 0 0 0 0 0
Other 0 0 16 30 16 24
Total 13 100 53 100 66 100
LVAD, Left ventricular assist device; INTERMACS, InteragencyRegistry forMechan-
ical Circulatory Support; RV, right ventricular; CNS, central nervous system. *In-
cludes right ventricular assist devices implanted at the time of or subsequent to left
ventricular assist device implantation.
TABLE 6. Causes of death in 1287 LVAD* destination therapy
patients: INTERMACS June 2006–December 2011
Primary cause
of death
Continuous flow pumps
Early
(1 mo) (n ¼ 72)
Later
(>1 mo) (n ¼ 176)
Total
(n ¼ 248)
No. % No. % No. %
Cardiac failure
RV failure 6 8 11 6 17 7
Arrhythmia/other 12 17 34 19 46 19
Infection 5 7 17 10 22 9
CNS event 8 11 15 9 23 9
Multiorgan failure 12 17 11 6 23 9
Respiratory failure 3 4 9 5 12 5
Bleeding
Gastrointestinal 2 3 2 1 4 2
Surgical 4 6 1 1 5 2
Other bleeding 5 7 13 7 18 7
Device failure 0 0 6 3 6 2
Renal failure 1 1 4 2 5 2
Hepatic failure 2 3 3 2 5 2
Malignancy 0 0 4 2 4 2
Arterial embolism 0 0 5 3 5 2
Cardiac tamponade 0 0 0 0 0 0
Withdrawal of support 1 1 8 5 9 4
Other 11 15 33 19 44 18
Total 72 100 176 100 248 100
LVAD, Left ventricular assist device; INTERMACS, InteragencyRegistry forMechan-
ical Circulatory Support; RV, right ventricular; CNS, central nervous system. *In-
cludes right ventricular assist devices implanted at the time of or subsequent to left
ventricular assist device implantation.
TABLE 7. Risk factors for death in destination therapy patients—
Adult primary implants: INTERMACS, June 2006–December 2011
Risk factors
Early hazard Constant hazard
HR P value HR P value
Age (older) 1.24* .01
BMI (higher) 1.04y .03
History of cancer 1.89 .04
History of cardiac surgery 1.69 .001
Dialysis 3.14 .004
BUN 1.08z .009
INTERMACS level 1 4.58 <.0001
INTERMACS level 2 2.35 .02
Use of pulsatile LVAD 2.63 <.0001
RVAD in same operation 3.22 .002
INTERMACS, Interagency Registry for Mechanical Circulatory Support; HR, hazard
ratio; BMI, body mass index; BUN, blood urea nitrogen; LVAD, left ventricular assist
device; RVAD, right ventricular assist device. *The hazard ratio denotes the increased
risk from 60 to 70 years. yThe hazard ratio denotes the increased risk of a 5-unit in-
crease in body mass index. zThe hazard ratio denotes the increased risk of a 10-unit
increase in blood urea nitrogen.
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3 to 7.
Pulsatile pump technology. In this experience, the use of
a pulsatile pump yielded inferior survival compared with
a current continuous flow device (Figure 12), in which the
1- and 2-year actuarial survivals were 76% and 67%. In
general, pulsatile pump patients were slightly older and
had somewhat worse renal and hepatic function than did
continuous flow patients (Table 9).
Quality of Life
On the basis of the EQ-5D quality of life instruments, pa-
tients receiving a continuous flow pump as DT noted a sig-
nificant reduction (P < .05) in both some and extreme
problems with mobility, self-care (Figure 13), usual activi-
ties of living (Figure 14), and anxiety/depression, compar-
ing before implant with 3, 6, and 12 months after implant.
In the area of pain and discomfort, significantly fewer pa-
tients noted this symptom complex after implant, but 6%
of patients interviewed continued to have extreme symp-
toms of pain and discomfort up to 1 year after LVAD im-
plant. The EQ-5D visual analog scale (see details under
Material and Methods) demonstrated prompt improvement
within 3 months after VAD implant, which was maintained
during the first year after implant (Figure 15).590 The Journal of Thoracic and Cardiovascular SurgCurrent Expected Survival After Cardiac
Transplantation
The current average survival after cardiac transplanta-
tion, as a benchmark for comparing posttransplant survival
against DT, is derived from the most recent Internationalery c September 2012
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FIGURE 8. Actuarial survival after destination therapy left ventricular as-
sist device (LVAD) support, stratified by age at implant. Patients are cen-
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DSociety for Heart and Lung Transplant Registry.5 The aver-
age 2-year risk-unadjusted survival in the most recent co-
hort is approximately 80% (Figure 16).
Survival Justification for Potential Triage From
Transplant to DT Therapy
If we use the non–risk-adjusted 2-year transplant survival
of 80% as an initial survival metric, generating solutions to
the multivariate equation provides insight into patient sub-
sets who would likely achieve the level of 2-year survival
that might begin to compete with transplantation.
Figure 17 depicts the age effect for a stable (INTERMACS
level 3 or greater) patient with preserved renal function and
without severe right ventricular failure who receives a con-
tinuous flow pump, stratified by the presence or absence of
prior cardiac operations. For the patient with prior cardiac
surgery, the 70% confidence limits overlap with a survival
of at least 80% at 2 years for patients less than about 40
years of age; but for the patient without prior cardiac sur-
gery, survival is likely to be at least 80% at 2 years forTABLE 8. Patient profile level—Adult primary implants:
INTERMACS, June 2006–December 2011, destination therapy
Level
June 2006–Dec 2009
(N ¼ 156)
No. (%)
Jan 2010–Dec 2011
(N ¼ 1131)
No. (%)
1. Critical cardiogenic shock 29 (18.6) 110 (9.7)
2. Progressive decline 64 (41.0) 422 (37.3)
3. Stable but
inotrope-dependent
36 (23.1) 346 (30.6)
4. Recurrent advanced HF 20 (12.8) 177 (15.6)
5. Exertion intolerant 2 (1.3) 43 (3.8)
6. Exertion limited 3 (1.9) 21 (1.9)
7. Advanced NYHA class III 2 (1.3)8 12 (1.1)
INTERMACS, Interagency Registry for Mechanical Assisted Circulatory Support;
HF, heart failure; NYHA, New York Heart Association.
The Journal of Thoracic and Capatients aged 62 years or less. Figure 18 displays the solu-
tion to the multivariable equation for a 60-year-old patient
with preserved renal function and without right ventricular
failure who receives a continuous flow pump, depicted for
various body mass indexes stratified by the presence or ab-
sence of prior cardiac surgery. Overall, about 20% of the
DT population experienced 2-year survival equal to or
greater than the transplant reference line of 80%
(Figure 19).DISCUSSION
Evolution of DT
As early as 1991, the Institute ofMedicine recognized the
importance of detailed longitudinal follow-up data on0
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LVAD: CFP, n=1136, deaths=235
LVAD: PFP, n=120, 
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FIGURE 10. Actuarial survival after destination therapy left ventricular
assist device (LVAD) support, stratified by device location and pump
type. Patients are censored at transplant or device explant for recovery.
CFP, Continuous flow pump; PFP, pulsatile flow pump; BIVAD, biventric-
ular assist device (implanted at time of LVAD implant).
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FIGURE 11. Bar chart indicating the timing of RVAD implant. LVAD,
Left ventricular assist device; RVAD, right ventricular assist device.
TABLE 9. Preimplant baseline characteristics: INTERMACS:
Primary implants—Implant dates: June 23, 2006–December 31,
2011, destination therapy
Preimplant characteristics
PFP
(N ¼ 127)
CFP
(N ¼ 1160)
P
value
Age (y) 54.70 63.56 <.0001
Albumin (g/dL) 3.19 3.38 .02
Total bilirubin (mg/dL) 1.59 1.37 .09
BMI (kg/m2) 32.40 28.14 <.0001
BNP (pg/mL) 1286.82 1255.79 .84
BSA (m2) 2.27 2.04 <.0001
BUN (mg/dL) 38.83 33.91 .01
Cholesterol (mg/dL) 117.93 126.80 .15
Cardiac index (L $ min1 $ m2) 2.09 2.15 .64
Creatinine (mg/dL) 1.81 1.54 .02
CRP (mg/L) 23.47 14.43 .39
Diastolic blood pressure (mm Hg) 61.46 62.89 .18
Hemoglobin (mg/dL) 11.20 11.33 .48
Heart rate 9185 84.91 <.0001
INR (international units) 1.38 1.33 .27
LVEDD 6.81 6.74 .58
Platelet (K/mL) 199.29 187.06 .09
Before albumin (mg/dL) 15.30 18.85 .0024
Protein C (%) 77.17 84.70 .59
Protein S (%) 70.29 77.47 .54
Pulmonary diastolic pressure (mm Hg) 29.35 24.61 <.0001
Pulmonary systolic pressure (mm Hg) 54.49 50.10 .01
Pulmonary wedge pressure (mm Hg) 26.75 23.21 .0035
PVR (Wood units) 3.08 2.75 .31
RA pressure (mm Hg) 15.75 11.35 <.0001
SGOT/AST (m/L) 122.94 54.23 .06
SGPT/ALT (m/L) 133.19 52.42 .01
Sodium (mmol/L) 134.23 134.99 .13
Systolic blood pressure (mm Hg) 99.40 104.90 .0004
WBC (K/mL) 9.86 8.39 .0008
INTERMACS, Interagency Registry for Mechanical Assisted Circulatory Support;
PFP, pulsatile flow pump; CFP, continuous flow pump; BMI, body mass index;
BNP, brain natriuretic peptide; BSA, body surface area; BUN, blood urea nitrogen;
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Dpatients receiving long-term MCS devices. Their report,
‘‘The Artificial Heart: Prototypes, Policies, and Patients,’’
supported development of a registry to followMCS patients
for the remainder of their lives; ‘‘.maintaining a Registry
of recipients should be considered a routine aspect of this
care. The committee recommends that NHLBI support
long-term studies.’’6
After more than a decade of MCS as bridge-to-transplant
therapy, the REMATCH (Randomized Evaluation of Me-
chanical Assistance for the Treatment of Congestive Heart
Failure) trial (conducted between 1998 and 2001),7 paved
the way for FDA approval of the HeartMate XVE for DT
in the United States, followed by the CMS decision for
Medicare coverage of DT in 2003. The prospect of wide-
spread application of MCS as long-term therapy for patients
with advanced heart failure provided the stimulus for the
NHLBI to develop a platform for long-term follow-up of
patients supported by MCS therapies. The resultant NHLBI0
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FIGURE 12. Actuarial survival among destination therapy patients, strat-
ified by device type. Patients are censored at the time of transplant or ex-
plant due to recovery. LVAD, Left ventricular assist device. *See notation
in Figure 4.
CRP, C-reactive protein; INR, international normalized ratio; LVEDD, left ventricular
end-diastolic dimension; PVR, pulmonary vascular resistance; RA, right atrial; SGOT/
AST, serum glutamic oxaloacetic transaminase/aspartate aminotransferase; SGPT/
ALT, serum glutamic pyruvate transaminase/alanine aminotransferase; WBC, white
blood cell count.
592 The Journal of Thoracic and Cardiovascular Surgcontract laid the foundation for INTERMACS, as an exten-
sion of the earlier recommendations from the Institute of
Medicine.
During the first 2 years of the INTERMACS experi-
ence, the landscape of approved device therapy was dom-
inated by pulsatile technology, inasmuch as continuous
flow pumps were largely still under investigation in clin-
ical trials.8 With the general recognition that the Heart-
Mate XVE device was prone to device malfunction with
the frequent need for reoperation within 12 to 18 months
(see again Figure 6), few such pumps were being im-
planted for DT. With escalating enthusiasm for continu-
ous flow technology in Europe and the United States,
many patients poorly suited for cardiac transplantationery c September 2012
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FIGURE 13. Percent of patients with some and extreme problems with
self care before and at intervals after destination therapy with a continuous
flow (CF) left ventricular assist device (LVAD). EQ-5D, Standardized in-
strument designed as a measure of health outcome and applicable to
a wide range of health conditions and treatments. See Materials and
Methods for further discussion of EQ-5D.
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EQ5D Visual Analog Scale (VAS) across time (mean ± SE)
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FIGURE 15. EQ-5D visual analog scale (VAS) (see Materials and
Methods for definition) before and at intervals after destination therapy
with a continuous flow pump. SE, Standard error; CF, continuous flow;
LVAD, left ventricular assist device. The other abbreviations are as in
Figure 13.
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Dreceived a continuous flow pump (approved for bridge-to-
transplant therapy in 2008) under the reimbursable ap-
proved indication of bridge to transplant.9 In reality, the
transplant status of this group of patients was ambiguous,
and MCS therapy was often applied as a strategy of
‘‘bridge to candidacy.’’9 Predictably, VADs implanted as
DT represented less than 10% of devices entered into IN-
TERMACS between 2006 and 2009.10 The marked in-
crease in pumps implanted as DT in 2010 and 2011
(more than 30% of total implants)8 coincided with the ap-
proval of the HeartMate II continuous flow pump for DT
in January of 2010.
This rapid evolution toward continuous flow technology
is poignantly reflected in the INTERMACS registry0
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FIGURE 14. Percent of patients with some or extreme problems with
usual activities before and at intervals after destination therapy with a con-
tinuous flow pump. The depiction and abbreviations are as in Figure 13.CF,
Continuous flow; LVAD, left ventricular assist device.
The Journal of Thoracic and Caduring the most recent era (see again Figure 2). Greater
than 95% of devices entered into INTERMACS in 2010
and 2011 were continuous flow pumps, and all DT devices
were continuous flow devices.9 The general enthusiasm
for continuous flow devices in DT strategies was also sup-
ported by the multi-institutional study of Park and
colleagues.11Reasons for Transplant Ineligibility
Despite the intended strategy of DT as a ‘‘permanent’’
therapy for advanced heart failure, the clinical reality is
that few therapies are exclusively ‘‘either/or’’ for theFIGURE 16. Survival after cardiac transplantation, stratified by era. NA,
Not applicable. (From Stehlik J, Edwards LB, Kucheryavaya AY, Benden
C, Christie JD, Dobbels F, et al. The Registry of the International Society
for Heart and Lung Transplantation: Twenty-eighth Adult Heart Transplant
Report—2011. J Heart Lung Transplant. 2011;30:1078-94. Reproduced
with permission of the International Society for Heart and Lung Transplan-
tation Registry.)
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FIGURE 19. Actuarial survival stratified by high-, medium-, and low-risk
patients. ‘‘Risk factors’’ include presence of biventricular support (BiVAD),
previous cancer, bodymass index (BMI) greater than 32, serum sodium less
than 130, or blood urea nitrogen (BUN) greater than 50. INTERMACS, In-
teragency Registry for Mechanically Assisted Circulatory Support; LVAD,
left ventricular assist device.
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Dduration of the heart failure patient’s life. Even with the
most successful MCS, patients will be followed up indefi-
nitely with scheduled reevaluations to determine whether
the device, heart transplantation, explant, or potentially
other therapies provide the greatest opportunity going for-
ward for the highest quality extended survival. The appreci-
ation of possible neutralization of certain transplant
contraindications after device implant was previously ad-
dressed by Kirklin and colleagues10 in categorizing such
contraindications as ‘‘modifiable’’ or ‘‘un-modifiable.’’
The challenge of clinical prescience regarding the revers-
ibility of many comorbid conditions is embodied in the des-
ignation ‘‘bridge to candidacy,’’ which is currently the most0
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Blood urea nitrogen; INTERMACS, Interagency Registry for Mechanically
Assisted Circulatory Support; Bi-VAD, biventricular support.
594 The Journal of Thoracic and Cardiovascular Surgcommon device strategy (not an FDA-approved indication)
among implant recipients9 in INTERMACS.
Outcome of Patients With Initial DT Strategy
Despite the potential impurity of the designation DT as
well as likely overlap (in terms of actually pursuing a course
of long-term VAD therapy) with other strategy designations
such as ‘‘bridge to candidacy,’’ this study was well suited to
critically analyze patients who received extended support
with durable devices. Other studies have made inferences
about ‘‘long-term’’ device therapy from patient popula-
tions8,12,13 ultimately committed to transplantation. The
‘‘censoring’’ of patients at time of transplant introduces
considerable uncertainty about long-term device potential,
in that patients with major device complications (which
would likely affect patient survival and quality of life if
the device was retained) often undergo transplantation at
an increased priority level, thereby potentially avoiding an
unfavorable VAD outcome. This study had relatively few
such patients, in that only about 10% of pulsatile device pa-
tients underwent transplantation during the study period,
and less than 5% of continuous flow patients (see again
Figures 4 and 5) were diverted to transplant.
Adverse Events
In the evaluation of patients potentially suitable for either
cardiac transplantation or MCS DT, the expected life satis-
faction during extended support will ultimately exert a ma-
jor influence on therapy selection for both practitioner and
patient. In this sense, therapy comparison and selection is
confounded by the striking differences in the adverse event
profiles of heart transplantation versus MCS. Whereas
transplantation is challenged by the complications of rejec-
tion, infection, malignancy, and allograft vasculopathy,14ery c September 2012
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device-related infection, bleeding events, right heart failure,
central nervous system events, and device malfunc-
tion.9,10,15 The concept of adverse event burden8 (see again
Table 4) might provide a unifying method of expressing the
overall adverse event impact of each therapy, but ultimately
the patient will need to participate in therapy selection
based, in part, on a subjective analysis of the relevant ad-
verse event profile and how that might affect life
satisfaction.
Survival
The pace of progress in effective extendedMCS has been
well chronicled since the original REMATCH publication
cited a 2-year survival less than 25% with the HeartMate
XVE as DT.7 Subsequent reports with the same pump
technology reported 2-year survival of nearly 60%.11
With continuous flow technology as bridge-to-transplant
therapy, 1-year survival improved from 68% in the original
HeartMate II bridge-to-transplant trial12 to 73% in the mid-
trial update.11 In the subsequent HeartMate II DT trial,
2-year survival improved from 58% in the early trial expe-
rience to 63% for the midtrial group.11 The clear survival
benefit of continuous flow technology over pulsatile pumps
for DT was documented in the INTERMACS analysis of
2011.10 Other studies indicate that survival improvements
have continued despite little change in overall patient
risk profile over the past 4 years.9 The trajectory of incre-
mental survival documented in this analysis is consistent
with improvements in the field of MCS over the past 5 to
8 years.
Risk Factors for DT
The NYHA class IV designation has become the major
descriptor of heart failure level sufficiently severe to war-
rant device therapy or transplantation, but it is widely recog-
nized that this encompasses different levels of clinical
decompensation. The current analysis identified patients
in cardiogenic shock to be at higher risk for mortality
with DT, a finding noted early in the INTERMACS experi-
ence.8 This finding was facilitated by the INTERMACS
subclassification of NYHA class IV for heart failure, in
which 5 INTERMACS profiles describe the various stages
of NYHA class IV (see again Appendix Table 3). After
the first year of data collection, over 40% of patients receiv-
ing durable devices were in acute decompensation (level 1,
cardiogenic shock). With the appreciation of the important
increment of mortality associated with implantation under
such unstable conditions, the proportion of patients receiv-
ing implants in shock fell to under 15% in 2010.9 Currently,
increasing proportions of patients are currently implanted in
the lower INTERMACS levels of NYHA class IV.
Right ventricular dysfunction severe enough to require
RVAD support was the greatest predictor of subsequentThe Journal of Thoracic and Camortality, which has been a consistent finding in prior
INTERMACS analyses.2,8,9,10 Precise definitions of
various degrees of right ventricular dysfunction have
proved challenging and have been recently modified to
better reflect clinical correlates (see Appendix Table 2).
Even the identification of severe right ventricular failure
by the need for RVAD support is rather subjective, inas-
much as the specific trigger for initiating RVAD placement
differs among experienced VAD surgeons. The importance
of identifying patients at risk for severe right ventricular
failure is evident, inasmuch as such patients on the trans-
plant list would be poor candidates for triage to DT VAD
therapy. INTERMACS has viewed right ventricular dys-
function to be such a critical issue that a scientific task force
is being assembled to address the issues of identification,
prevention, and management of the failing right ventricle
during LVAD support.
Quality of Life
The findings of improved quality-of-life indicators as
judged by the EQ-5D instrument are consistent with
improvements in quality of life and functional status using
theMinnesota Living with Heart Failure Questionnaire.16,17
and the Kansas City Cardiomyopathy Questionnaire18 in
the HeartMate II device trial.19,20 Other studies have
shown substantial improvement in the 6-minute walk test
after implant.20 Similar positive findings were reported by
Park and colleagues.11 Although a myriad of studies have
documented improvement in quality of life and functional
outcome indicators after heart transplantation,21,22 few
studies have directly compared transplantation withMCS.23
Survival Justification to Triage From Transplant to
DT Therapy
The solutions to the risk factor model provide insight into
the types of patients who, depending on their comorbidities
for cardiac transplantation, might warrant consideration for
triage to DT MCS with continuous flow technology. The
profile of such patients would currently include preserved
renal function, absence of severe right ventricular failure,
stable cardiovascular function on inotropic support, and
body mass index suitable for transplant. Currently, the
model does not justify triage to DT if the patient has under-
gone previous cardiac operations except for relatively
young patients, a group less likely to select long-term
pump support unless they were highly sensitized. Although
this model would not yet support tapping into the large co-
hort of patients with prior cardiac operations, details of that
decision-making process would depend on risk factor mod-
eling within the transplant population to seek subsets whose
predicted 2-year survival might be less than 80%. Realizing
that inferences are being drawn from a group of patients
considered ineligible for cardiac transplantation, the strati-
fied actuarial depiction in Figure 19 suggests that nearlyrdiovascular Surgery c Volume 144, Number 3 595
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that would be competitive with the ‘‘average’’ transplant
patient.
If such triage decisions did occur, a paradigm shift of this
magnitude in the arena of advanced heart failure would cer-
tainly accelerate the pace of device implants and potentially
affect listing criteria at major heart transplant centers as
well as allocation algorithms. Major challenges to ensure
truly informed patient decisions regarding device therapy
versus transplantation would further confound decisions
in this evolving platform of heart failure care.
Of course, the primary metric would be survival, but sur-
vival at what interval? Is predicted 2-year survival of suffi-
cient duration for such a paradigm shift? In great measure
the answer depends on the ‘‘expected’’ trajectory of the sur-
vival curve beyond 2 years, inasmuch as the possibility ap-
pears remote that patients and providers will await 5 more
years of patient follow-up, a randomized trial of VAD ver-
sus transplant, or other longitudinal analyses before begin-
ning the ‘‘shift.’’ Societal and health care ‘‘impatience’’ is
already evident with the ‘‘REVIVE IT’’ trial, which allo-
cates long-term device therapy possibly before the patient
would normally be considered for transplantation.
Another imponderable in this therapeutic allocation pro-
cess is the clear knowledge that the patients with a DT de-
vice can always be reconsidered for cardiac transplantation
if device complications or other impairments in quality of
life tip the balance toward transplantation. Other unin-
tended consequences may occur: the whole priority alloca-
tion for other patients awaiting transplantation may be
affected, and hospitals without expertise in transplant sur-
gery and medicine may preferentially (and possibly inap-
propriately) offer devices rather than transplant to
transplant-eligible patients.
Once this ‘‘magic metric’’ of survival (eg, 80% at 2
years) is accepted for devices in the advanced heart failure
community, other metrics that majorly affect the quality of
patient existence will assume center stage in our ongoing
analyses. For just that reason, quality of life and functional
outcome indicators represent a major INTERMACS focus
in future analyses.
In considering specific patients for triage from transplan-
tation to device therapy, the presence of noncardiac comor-
bidities is known to impair long-term survival after cardiac
transplantation, as has been quantified in an analysis from
the Cardiac Research Database.24 Another important group
of patients for potential triage are those who are highly sen-
sitized with circulating anti-HLA antibodies. The opportu-
nity for DT could provide an important benefit for these
sensitized patients who frequently endure long waiting
times while continuing to experience symptoms of ad-
vanced heart failure. Ultimately, the triage of these higher
risk transplant subsets could increase the survival utility
of the precious and limited resource of donor hearts.596 The Journal of Thoracic and Cardiovascular SurgStudy Limitations
Inferences from this database have important strengths
and weaknesses. The strengths include the scope and rigor
of INTERMACS. As an NHLBI initiative, INTERMACS
engages National Institutes of Health oversight, follows Ob-
servational Study Monitoring Board surveillance, and re-
quires performance standards of participating institutions.
The power of INTERMACS is further enhanced by the
CMSmandate for data submission on all approved and con-
sented durable MCS devices implanted at centers approved
for DT therapy, formal definitions and processes for adjudi-
cation of adverse events, dedicated electronic data submis-
sion, compulsive data monitoring, and a hospital auditing
process, all of which raise INTERMACS close to the rigor
of a clinical trial. Indeed, the quality and completeness of
data collection have been of sufficient quality that the
FDA has embraced the use of INTERMACS patients as
‘‘concurrent controls’’ in at least 1 pivotal clinical device
trial,25 and the INTERMACS platform has been held in
high regard by the NHLBI.1
However, important study limitations relate to the knowl-
edge that INTERMACS does not represent a complete sam-
ple of DT patients. Follow-up is not available for patients
who do not provide informed consent, which represents
about 9.6% of available patients with FDA-approved de-
vices. One could speculate about whether these patients
represent a higher risk group. Furthermore, all patients
who receive DT therapy as part of a clinical device trial
are excluded from INTERMACS. Finally, maximal
follow-up of continuous flow DT patients is only now ex-
ceeding 2 years, generating uncertainty about truly long-
term survival.CONCLUSIONS
1. DT represents an increasing LVAD application and cur-
rently accounts for nearly one third of overall MCS ac-
tivity in the United States.
2. Evolution from pulsatile to continuous flow technology
has dramatically improved 1- and 2-year survivals.
3. DT is not appropriate for patients with rapid hemody-
namic deterioration or cardiogenic shock.
4. The presence of severe right ventricular failure is a con-
traindication for DT.
5. Important subsets of DT patients now enjoy survival that
may be competitive with heart transplantation out to
about 2 years.
6. Future studies will focus on transplant-eligible subsets
who may benefit from informed discussions about
MCS as an alternative long-term option.We acknowledge the skilled participation of Ms Susan Meyers
in all areas of the analyses and Ms Peggy Holmes in manuscript
preparation.ery c September 2012
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Dr Soon J. Park (Rochester, Minn). Dr Kirklin and his col-
leagues are to be congratulated for this timely and important pre-
sentation. They report that a significant fraction of DT patients are
achieving a survival that is comparable with that of those who un-
dergo heart transplantation. Such finding is especially astonishing
in that these patients, by definition, were those deemed inappropri-
ate to allocate donor hearts for the concern of poor posttransplant
outcome.
Perhaps it is helpful to revisit the medical ethics governing
heart transplantation, which was established well before the cur-
rent development in LVAD therapy. Heart transplantation has
been the only therapeutic option capable of prolonging life in
these patients with end-stage heart failure. Although it is highly
effective on an individual level, its epidemiologic impact has
been trivial for there exists a significant mismatch between donors
and recipients. The donor heart remains a precious and scarce re-
source for society. Therefore, the practice of heart transplantation
has been guided by principles of justice, utility, and transplant
benefit to maximize the number of years gained by the
transplantation.
With the recent development in LVAD therapy, heart transplant
no longer seems to be the only viable option. Now, LVAD therapy
can be rendered immediately and abundantly, and it is going to
change the natural history of patients with end-stage heart failure
dramatically, whether transplant eligible or not.
As we have just been informed by Dr Kirklin, a significant frac-
tion of patients who were destined to die because heart transplant
was not an option, a typical scenario of despair that affects the vast
majority of patients, are now able to enjoy life on LVAD support.
In regard to the transplant-eligible patients, many medical cen-
ters seem to witness a significantly enhanced rate of survival in
these bridge-to-transplant patients compared with DT patients.
What is the INTERMACS bridge-to-transplant experience? How
does it compare with the attrition rate of 4% due to various causes
such as rejection, infection, allograft vasculopathy, and malig-
nancy after transplantation? What would be the appropriate
LVAD strategy in terms of patient selection, duration of support,
and timing of triggering transplantation in accordance with the
principles of transplantation? Finally, would it ever make sense
to consider LVAD as the primary therapy and reserve heart trans-
plantation as a secondary therapy?
I would welcome Dr Kirklin’s insight into some of these ques-
tions, and, once again, congratulations for ushering in a truly excit-
ing period of LVAD therapy.
Dr Kirklin. Thank you, Dr Park. Those are interesting
questions.rdiovascular Surgery c Volume 144, Number 3 597
Acquired Cardiovascular Disease Kirklin et al
A
C
DYou asked about the mortality or attrition rate with cardiac
transplantation versus ventricular support. In the INTERMACS
database, recall that the continuous flow technology is really
now only exceeding 2 years, and during that time in the low-risk
group, the mortality rate is about 10% per year, which compares
with about 6% per year in the constant phase after cardiac trans-
plantation. Thus it is not quite there yet, even though there are spe-
cific risk factor groups that are competitive out to 2 years. Of
course, the mechanical support group includes older patients; the
median age in the INTERMACS DT group was 67 years versus
55 years in the transplant group.
Regarding the issue of using LVAD therapy as primary therapy
and transplantation secondary, of course, the goal in the future will
be to have an array of therapies that maximizes long-term survival
for patients. Whether that means initial VAD therapy followed by
transplant or initial transplant followed by a total artificial heart
will depend on the kinds of rigorous analyses that we will need
to do in the future. There is going to be the requirement for rigor-
ous transplant databases to get risk-appropriate patients as well as
ongoing analyses of these mechanical support databases.
Dr John V. Conte (Baltimore, Md). Dr Kirklin, congratulations
on a very thought-provoking paper. Having heard you say about 2
years ago that mechanical support would not be equivalent of heart
transplantation at this point in time, it is refreshing to hear that you
have somewhat changed your tone based on these data. Are you
ready right now to refer this subset of patients for mechanical sup-
port rather than transplantation? If not, what duration of long-term
follow-up would you consider necessary before you would refer
that subset of patients you just presented?
Finally, is there a financial consideration in referring this sub-
group of patients for long-term therapy?What role do the econom-
ics of transplantation andmechanical support play in this decision?
Dr Kirklin. The actual identification of patients on the trans-
plant list who could be triaged to mechanical support will depend,
of course, on their comorbidities, and there are analyses available
from previous experiences that would allow us to begin that triage
effort. Currently, however, it is going to be challenging, because
there is more contemporary data about risk stratification in
MCS patients, ironically, than there is in the current era of cardiac
transplantation. It is appropriate to begin triaging certain pa-
tients—those with multiple comorbidities who are likely to have
a long wait for cardiac transplantation, such as sensitized patients.598 The Journal of Thoracic and Cardiovascular SurgThe financial implications are complicated and will have to be
determined by societal as well as medical priorities. Clearly, we
are going to be looking at the financial implications over decades
of patient care if we are going to be using a combination of me-
chanical support, transplantation, and potentially other therapies.
Dr Conte. To answer the question directly, are you ready as you
stand there today to refer that subgroup of patients for DT as op-
posed to transplantation? I am going to hang you on your words.
Dr Kirklin. Yes.
DrR. Duane Davis (Durham, NC).Congratulations. I just want
to be a little bit cautious when you use that 20% 2-year survival in
heart transplant as your benchmark and then compare a 40-year-
old who has never had surgery getting a VAD and saying it is
equivalent. If you did a 40-year-old who never had previous car-
diac surgery, the 2-year mortality would not be 20% after a heart
transplant. It is clear that continuous VAD is getting into the ball-
park, but I am not sure I am ready to agree that it is equivalent.
Finally, when are we going to be ready to randomize between
those 2 therapies?
Dr Kirklin. The challenge in transplantation is to begin to set
some benchmark about which we could begin to have this discus-
sion, and I think a benchmark of 20% mortality at 2 years is cer-
tainly reasonable. Remember that the low-risk, 40-year-old
patient undergoing cardiac transplantation without important other
comorbidities is not the patient one would want to triage to me-
chanical support. The reason this benchmark is important is to be-
gin the discussion of those kinds of patients who could potentially
be triaged if they are a low enough risk with device therapy. How-
ever, it will only be those patients who are on the transplant list
with multiple adverse comorbidities that we are going to initially
select for triage. It will not be the otherwise healthy 40-year-old
man with a good long-term expectation from cardiac
transplantation.
Dr Joseph Amato (Chicago, Ill). Dr Kirklin, Dr Pagani, I con-
gratulate you on your work. Last week, I was at the FDA meeting
in regard to the INTERMACS pump. I witnessed the pump in ac-
tion, and all the other committee members there approved this dy-
namic pump. I disagree with the comments made in regard to the
continued improvement in searching for a bridge to transplant and
that the impact as mentioned is trivial. The experience in Europe
has been highly successful and we await a smaller version. It is
a compact and beautiful little pump.ery c September 2012
APPENDIX TABLE 1. Information collected in the interagency registry for mechanically assisted circulatory support database
Data collected Preimplant Implant 1 wk/1 mo Discharge 3 mo/every 6 mo
Demographic x
Medical support status x
Comorbidities x
Hemodynamics x x x x
Medications x x x x
Laboratory x x x x
Medical condition x x x
Exercise function x x
Patient status x x
Device information x
Device details x
Device parameters x x
Quality of life x x
Trail Making Test x x
Adverse event reminders x x x
Chronology of hospital time x
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APPENDIX TABLE 2. Major adverse events collected in
INTERMACS
Major Bleeding
AN EPISODE OF SUSPECTED INTERNAL OR EXTERNAL
BLEEDING THAT RESULTS IN ONE OR MORE OF THE
FOLLOWING:
1. Death
2. Reoperation
3. Hospitalization
4. Transfusion of red blood cells
If TRANSFUSION IS SELECTED, then apply the following rules:
During first 7 d after implant:
 Adults (50 kg): 4 U of packed red blood cells within any 24
hour period during the first 7 d after implant.
After 7 d following implant
 Any transfusion of packed red blood cells after 7 d following
implant with the investigator recording the number of units
given.
Note: Hemorrhagic stroke is considered a neurologic event and not as
a separate bleeding event.
Cardiac Arrhythmias
Any documented arrhythmia that results in clinical compromise
(eg, diminished VAD flow, oliguria, presyncope, or syncope) that
requires hospitalization or occurs during a hospital stay. Cardiac
arrhythmias are classified as 1 of 2 types:
1. Sustained ventricular arrhythmia requiring defibrillation or
cardioversion.
2. Sustained supraventricular arrhythmia requiring drug treatment or
cardioversion.
Pericardial Fluid Collection
Accumulation of fluid or clot in the pericardial space that requires surgical
intervention or percutaneous catheter drainage. This event will be
subdivided into those with clinical signs of tamponade (eg, increased
central venous pressure and decreased cardiac/VAD output) and those
without signs of tamponade.
Device Malfunction
Device malfunction denotes a failure of one or more of the components of
the MCS device system that either directly causes or could potentially
induce a state of inadequate circulatory support (low cardiac output
state) or death. The manufacturer must confirm device failure. A failure
that was iatrogenic or recipient-induced will be classified as an
Iatrogenic/Recipient-induced Failure.
Device failure should be classified according to which components fails
as follows:
1. Pump failure (blood-contacting components of the pump and any
motor or other pump-actuating mechanism that is housed with the
blood-contacting components). In the special situation of pump
thrombosis, thrombus is documented to be present within the device
or its conduits that result in or could potentially induce circulatory
failure.
2. Nonpump failure (eg, external pneumatic drive unit, electric power
supply unit, batteries, controller, interconnect cable, compliance
chamber).
Hemolysis
A plasma-free hemoglobin value that is greater than 40 mg/dL, in
association with clinical signs associated with hemolysis (eg, anemia,
low hematocrit, hyperbilirubinemia) occurring after the first 72 h after
(Continued)
APPENDIX TABLE 2. Continued
implant. Hemolysis related to documented non–device-related causes
(eg, transfusion or drug) is excluded from this definition.
Hepatic Dysfunction
An increase in any 2 of the following hepatic laboratory values (total
bilirubin, aspartate aminotransferase/AST and alanine
aminotranferease/ALT) to a level greater than 3 times the upper limit of
normal for the hospital, beyond 14 d after implant (or if hepatic
dysfunction is the primary cause of death).
Hypertension
New-onset blood pressure elevation greater than or equal to 140 mm Hg
systolic or 90 mm Hg diastolic (pulsatile pump) or 110 mm Hg mean
pressure (rotary pump).
Pediatric patients: For patients under 18 y of ageweighing less than 50 kg,
hypertension is defined as systolic, diastolic, or mean blood pressure
greater than the 95th percentile for age that requires the addition of
intravenous or oral therapy for management.
Major Infection
A clinical infection accompanied by pain, fever, drainage, and/or
leukocytosis that is treated by antimicrobial agents (nonprophylactic). A
positive culture from the infected site or organ should be present unless
strong clinical evidence indicates the need for treatment despite negative
cultures. The general cateogories of infection are listed below:
Localized Nondevice Infection
Infection localized to any organ system or region (eg, mediastinitis)
without evidence of systemic involvement (see sepsis definition),
ascertained by standard clinical methods and either associated with
evidence of bacterial, viral, fungal or protozoal infection, and/or
requiring empirical treatment.
Percutaneous Site and/or Pocket Infection
A positive culture from the skin and/or tissue surrounding the driveline
or from the tissue surrounding the external housing of a pump
implanted within the body, coupled with the need to treat with
antimicrobial therapy, when there is clinical evidence of infection
such as pain, fever, drainage, or leukocytosis.
Internal Pump Component, Inflow or Outflow Tract Infection
Infection of blood-contacting surfaces of the LVAD documented by
positive site culture. (There should be a separate data field for
paracorporeal pump that describes infection at the percutaneous
cannula site, eg, Thoratec PVAD).
Sepsis
Evidence of systemic involvement by infection, manifested by positive
blood cultures and/or hypotension.
Myocardial Infarction
Two categories of myocardial infarction will be identified:
Perioperative Myocardial Infarction
The clinical suspicion of myocardial infarction together with creatine
kinase MB or troponin greater than 10 times the local hospital upper
limits of normal, found within 7 d after VAD implant together with
electrocardiographic findings consistent with acute myocardial
infarction. (This definition uses the higher suggested limit for serum
markers owing to apical coring at the time of VAD placement and does
not usewall motion changes because the apical sewing ring inherently
creates new wall motion abnormalities.)
(Continued)
Acquired Cardiovascular Disease Kirklin et al
600 The Journal of Thoracic and Cardiovascular Surgery c September 2012
A
C
D
APPENDIX TABLE 2. Continued
Nonperioperative Myocardial Infarction
The presence more than 7 d after implant of 2 of the following 3 criteria:
1. Chest pain that is characteristic of myocardial ischemia
2. Electrocardiogram with a pattern or changes consistent with
a myocardial infarction
3. Troponin or creatine kinase (measured by standard clinical
pathology/laboratory medicine methods) greater than the normal
range for the local hospital with positive MB fraction (3% total
creatine kinase). This should be accompanied by a new regional left
or right ventricular wall motion abnormality on a myocardial
imaging study.
Neurologic Dysfunction
Any new, temporary or permanent, focal or global neurologic deficit
ascertained by a standard neurologic examination (administered by
a neurologist or other qualified physician and documented with
appropriate diagnostic tests and consultation note). The examining
physician will distinguish between a transient ischemic attack, which is
fully reversible within 24 h (and without evidence of infarction), and
a stroke, which lasts longer than 24 h (or<24 h if there is evidence of
infarction). The NIH Stroke Scale (for patients>5 y old) must be
readministered at 30 and 60 d after the event to document the presence
and severity of neurologic deficits. Each neurologic event must be
subcategorized as:
1. Transient ischemic attack (acute event that resolves completely within
24 h with no evidence of infarction)
2. Ischemic or hemorrhagic cardiovascular accident (event that persists
beyond 24 h or<24 h associated with infarction on an imaging study.
In addition to the above, for patients less than 6 mo of age, any of the
following:
3. New abnormality of head ultrasound
4. Electroencephalogram positive for seizure activity with or without
clinical seizure
Psychiatric Episode
Disturbance in thinking, emotion or behavior that causes substantial
impairment in functioning or marked subjective distress requiring
intervention. Intervention is the addition of new psychiatric medication,
hospitalization, or referral to a mental health professional for treatment.
Suicide is included in this definition.
Renal Dysfunction
Two categories of renal dysfunction will be identified:
Acute Renal Dysfunction
Abnormal kidney function requiring dialysis (including hemofiltration)
in patients who did not require this procedure before implant, or a rise
in serum creatinine of greater than 3 times baseline or greater than 5
mg/dL (in children, creatinine greater than 3 times the upper limit of
normal for age) sustained for over 48 h.
Chronic Renal Dysfunction
An increase in serum creatinine of 2 mg/dL or greater above baseline, or
requirement for hemodialysis sustained for at least 90 d.
Respiratory Failure
Impairment of respiratory function requiring reintubation, tracheostomy, or
(for patients>age 5 y) the inability to discontinue ventilatory support
within 6 d (144 h) after VAD implant. This excludes intubation for
reoperation or temporary intubation for diagnostic or therapeutic
procedures.
(Continued)
APPENDIX TABLE 2. Continued
Right Heart Failure
Symptoms and signs of persistent right ventricular dysfunction (central
venous pressure>18mmHgwith a cardiac index<2.0 L $min1 $m2 in
the absence of elevated left atrial/pulmonary capillary wedge pressure
[greater than 18 mm Hg], tamponade, ventricular arrhythmias, or
pneumothorax) requiring RVAD; implantation; or requiring inhaled
nitric oxide or inotropic therapy for a duration of more than 1 week at
any time after LVAD implantation.’’
Arterial Non–Central Nervous System Thromboembolism
An acute systemic arterial perfusion deficit in any noncerebrovascular
organ system owing to thromboembolism confirmed by 1 or more of the
following:
1. Standard clinical and laboratory testing
2. Operative findings
3. Autopsy findings
This definition excludes neurologic events.
Venous Thromboembolism Event
Evidence of venous thromboembolic event (eg, deep vein thrombosis,
pulmonary embolism) by standard clinical and laboratory testing.
Wound Dehiscence
Disruption of the apposed surfaces of a surgical incision, excluding
infectious etiology, and requiring surgical repair.
Other
An event that causes clinically relevant changes in the patient’s health (eg,
cancer).
INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support;
VAD, Ventricular assist device; MCS, Mechanical circulatory support; LVAD, Left
ventricular assist device; RVAD, Right ventricular assist device; PVAD, paracorporeal
ventricular assist device; NIH, National Institutes of Health.
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APPENDIX TABLE 3. INTERMACS (Preimplant) Levels: Levels 1
through 5 are degrees of NYHA class IV
INTERMACS 1: Critical cardiogenic shock describes a patient who is
‘‘crashing and burning,’’ in which a patient has life-threatening
hypotension and rapidly escalating inotropic pressor support, with
critical organ hypoperfusion often confirmed by worsening acidosis and
lactate levels.
INTERMACS 2: Progressive decline describes a patient who has been
demonstrated ‘‘dependent’’ on inotropic support but nonetheless shows
signs of continuing deterioration in nutrition, renal function, fluid
retention, or other major status indicators. Patient profile 2 can also
describe a patient with refractory volume overload, perhaps with
evidence of impaired perfusion, in whom inotropic infusions cannot be
maintained owing to tachyarrhythmias, clinical ischemia, or other
intolerance.
INTERMACS 3: Stable but inotrope dependent describes a patient who is
clinically stable on mild to moderate doses of intravenous inotropes (or
has a temporary circulatory support device) after repeated
documentation of failure to wean without symptomatic hypotension,
worsening symptoms, or progressive organ dysfunction (usually renal).
It is critical to monitor nutrition, renal function, fluid balance, and
overall status carefully to distinguish between a patient who is truly
stable at patient profile 3 and a patient who has unappreciated decline
rendering them patient profile 2. This patient may be either at home or in
the hospital.
INTERMACS 4: Resting symptoms describes a patient who is at home
on oral therapy but frequently has symptoms of congestion at rest or
with activities of daily living. He or she may have orthopnea,
shortness of breath during activities of daily living such as dressing or
bathing, gastrointestinal symptoms (abdominal discomfort, nausea,
poor appetite), disabling ascites, or severe lower extremity edema.
This patient should be carefully considered for more intensive
management and surveillance programs, by which some may be
recognized to have poor compliance that would compromise
outcomes with any therapy.
INTERMACS 5: Exertion intolerant describes a patient who is
comfortable at rest but unable to engage in any activity, living
predominantly within the house or housebound. This patient has no
congestive symptoms but may have chronically elevated volume status,
frequently with renal dysfunction, and may be characterized as exercise
intolerant.
INTERMACS 6: Exertion limited also describes a patient who is
comfortable at rest without evidence of fluid overload, but who is able to
do some mild activity. Activities of daily living are comfortable and
minor activities outside the home such as visiting friends or going to
a restaurant can be performed, but fatigue results within a fewminutes of
any meaningful physical exertion. This patient has occasional episodes
of worsening symptoms and is likely to have had a hospitalization for
heart failure within the past year. This category describes NYHA class
IIIB.
INTERMACS 7: Advanced NYHA class III describes a patient who is
clinically stable with a reasonable level of comfortable activity, despite
a history of previous decompensation that is not recent. This patient is
usually able to walk more than a block. Any decompensation requiring
intravenous diuretics or hospitalization within the previous month
should make this person a patient profile 6 or lower.
INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support;
NYHA, New York Heart Association.
APPENDIX TABLE 4. Variables examined in risk factor analysis
Demographics
Age
Male
White
Black
Height, cm
Weight, kg
Body surface area (BSA)
Marital status
Laboratory value
Sodium
Albumin
Bilirubin
Blood urea nitrogen (BUN)
Creatinine
Cholesterol
Clinical
Protein C
C-reactive protein (CRP)
Blood type
Diagnosis—congenital
Diagnosis—coronary artery disease
History of coronary artery bypass grafting (CABG)
History of cardiac surgery
Implantable cardiac defibrillator (ICD)
Inotropes
Diabetes
Chronic obstructive pulmonary disease (COPD)
Ascites
Peripheral vascular disease
Cardiovascular accident
Previous cancer
Current smoker
Alcohol abuse
New York Heart Association (NYHA)
Hemodynamics
Systolic blood pressure
Left ventricular ejection fraction<20
Patient profile levels
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Level 7
Implant information
Left ventricular assist device (LVAD)
Right ventricular assist device (RVAD)
Biventricular assist device (BIVAD)
Concomitant surgery
Left ventricular assist device, continuous flow
Left ventricular assist device, pulsatile flow
Preimplant interventions
Ventilator
Dialysis
Intra-aortic balloon pump
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APPENDIX TABLE 5. Multivariable equations for risk models
The parametric model is specified in the cumulative hazard (A) domain as
the sum of 2 phases:
Lðt;QÞ ¼PJj¼1 mjðxj;bjÞGjðt;QjÞ
Where t is time, mj is the log-linear parametric scaling function of
concomitant information, and Gj is the parametric shaping function for
each of the 2 phases.
The hazard function l is the time derivative of the cumulative hazard
function
lðt;QÞ ¼PJj¼1 mjðxj;bjÞgjðt;QjÞ
Early hazard phase:
Gt ¼

1þ

BðtÞ
r
1=v1=m
gt ¼

1þ

BðtÞ
r
1=v 1
m
1BðtÞ
r
 1
v
1
vBðtÞ
vt
1
mvr
r ¼ Bðt1=2Þ½2m1v
Constant hazard phase:
and
G2 ¼ t
g2 ¼ 1
The maximum likelihood estimates of the parameters are:
t1/2 ¼ 1.0868
n ¼ 1.0316
m ¼ 1.0
me ¼ 0.04381
mc ¼ 0.00615
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